Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan

Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatini...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Current oncology (Toronto) 2025-01, Vol.32 (1), p.36
Hauptverfasser:	Kuo, Jerry Shu-Hung, Chang, Cheng-Yu, Chang, Shih-Chieh, Wei, Yu-Feng, Chen, Chung-Yu
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib EGFR mutation lung cancer Osimertinib rebiopsy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!